Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RANJIT R NAIR

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1407055221
CMS profile
1115162
Location
N.RICHLAND HILLS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$26,989.51

191 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RANJIT R NAIR

NPI 1407055221 · CMS profile ID 1115162

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

N.RICHLAND HILLS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407055221?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RANJIT R NAIR, NPI 1407055221, CMS profile ID 1115162. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407055221?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RANJIT R NAIR, NPI 1407055221, CMS profile ID 1115162. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407055221?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RANJIT R NAIR, NPI 1407055221, CMS profile ID 1115162, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1407055221?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

191 matching records · $26,989.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 191 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 191.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $14.6307/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104427277 CMS
Amgen Inc. $8.2507/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115958018 CMS
GlaxoSmithKline, LLC. $12.2807/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116283147 CMS
GENZYME CORPORATION $18.2107/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139750459 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.1707/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137640964 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.5807/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137640966 CMS
Inspire Medical Systems, Inc. $13.4907/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148087051 CMS
Vifor Pharma, Inc. $29.3007/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124052330 CMS
AstraZeneca Pharmaceuticals LP $19.8106/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104675309 CMS
Regeneron Healthcare Solutions, Inc. $23.2506/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114121817 CMS
Mylan Specialty L.P. $14.9206/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147291784 CMS
Amgen Inc. $18.3606/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115958012 CMS
AstraZeneca Pharmaceuticals LP $14.3706/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105664020 CMS
GlaxoSmithKline, LLC. $7.0206/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116068739 CMS
Amgen Inc. $5.6706/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115958008 CMS
GlaxoSmithKline, LLC. $12.5706/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116437257 CMS
Actelion Pharmaceuticals US, Inc. $121.8606/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078918233 CMS
GENZYME CORPORATION $22.3006/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139750455 CMS
Actelion Pharmaceuticals US, Inc. $31.1306/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078918239 CMS
AstraZeneca Pharmaceuticals LP $1,400.0006/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105505342 CMS
GENZYME CORPORATION $37.5006/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139750457 CMS
United Therapeutics Corporation $19.5306/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149444288 CMS
Optinose US, Inc. $26.8106/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142189924 CMS
GlaxoSmithKline, LLC. $12.3405/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116608332 CMS
Itamar Medical Inc $36.8505/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154007005 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.1205/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137640962 CMS
GlaxoSmithKline, LLC. $20.1405/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116546179 CMS
AstraZeneca Pharmaceuticals LP $14.0705/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105675177 CMS
Inspire Medical Systems, Inc. $10.3805/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148087047 CMS
Inspire Medical Systems, Inc. $6.0505/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148087043 CMS
GlaxoSmithKline, LLC. $34.1805/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116546689 CMS
HARMONY BIOSCIENCES LLC $20.3405/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126092298 CMS
GlaxoSmithKline, LLC. $23.2905/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116309867 CMS
Amgen Inc. $6.7805/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115958004 CMS
Baxter Healthcare $17.6705/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120665800 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.7705/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137640960 CMS
Mylan Specialty L.P. $1,869.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147283256 CMS
Mylan Specialty L.P. $117.2305/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147285768 CMS
Amgen Inc. $7.6005/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115957997 CMS
Novartis Pharmaceuticals Corporation $13.6105/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087073156 CMS
AstraZeneca Pharmaceuticals LP $27.6705/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104648559 CMS
JAZZ PHARMACEUTICALS INC. $9.7104/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150213095 CMS
GlaxoSmithKline, LLC. $13.0604/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116052742 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.6904/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137640958 CMS
GENZYME CORPORATION $13.2304/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139750443 CMS
HARMONY BIOSCIENCES LLC $16.0004/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126092300 CMS
Axsome Therapeutics, Inc. $29.7804/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148313552 CMS
ZOLL Respicardia, Inc. $14.6004/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146936349 CMS
Avadel CNS Pharmaceuticals, LLC $17.4104/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123385616 CMS
Actelion Pharmaceuticals US, Inc. $32.6704/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078918235 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $18,630.84 120
PY2020 $5,084.48 36
PY2021 $5,629.72 57
PY2022 $21,575.50 125
PY2023 $24,254.26 155
PY2024 $26,989.51 191
PY2025 $30,526.90 240

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $285,042.70 11
PY2024 Principal investigator $181,095.12 34
PY2023 Principal investigator $164,951.60 1
PY2022 Principal investigator $149,799.71 2
PY2021 Principal investigator $244,864.30 4
PY2020 Principal investigator $7,242.10 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $496.14 11/19/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184262599
Principal investigator 1 AstraZeneca Pharmaceuticals LP $263.00 11/10/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) No dispute reported 06/30/2026 1185550195
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16.05 06/11/2025 Non-covered Recipient Entity
The Lung and Sleep Research Institute of North Texas
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744954
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,250.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,535.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,500.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $974.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/23/2025 Non-covered Recipient Entity
THE LUNG AND SLEEP RESEARCH INSTITUTE OF NORTH TEXAS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188619
Principal investigator 1 AstraZeneca Pharmaceuticals LP $264,331.19 03/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) No dispute reported 06/30/2026 1185550193
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,177.32 02/10/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS MD ANDERSON CLINICAL CANCER PREVENTION
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001) No dispute reported 06/30/2026 1185550197